Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: Results of a randomized, placebo-controlled trial

Climacteric

Volumn 18, Issue 2, 2015, Pages 226-232

  Constantine, G ^a   Graham, S ^b   Portman, D J ^c   Rosen, R C ^d   Kingsberg, S A ^e  

^a EndoRheum Consultants LLC   (United States)

^b SHIONOGI AND CO LTD   (Japan)

^c Columbus Center for Women's Health Research ^*  (United States)

^d NEW ENGLAND RESEARCH INSTITUTES   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

dyspareunia; Female sexual dysfunction; menopause; ospemifene; tissue selective estrogen agonist antagonist; vulvar and vaginal atrophy

Indexed keywords

OSPEMIFENE; PLACEBO; SEX HORMONE; TESTOSTERONE; HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; FEMALE; FEMALE SEXUAL DYSFUNCTION; FEMALE SEXUAL FUNCTION INDEX; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; ORGASM; PAIN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL AROUSAL; SEXUAL FUNCTION; SEXUAL SATISFACTION; SEXUALITY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINAL LUBRICATION; VULVA DISEASE; AGED; ANALOGS AND DERIVATIVES; ATROPHY; BLOOD; CLINICAL TRIAL; PATHOLOGY; QUESTIONNAIRE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; VAGINA; VULVA;

AGED; ATROPHY; DOUBLE-BLIND METHOD; DYSPAREUNIA; FEMALE; HORMONES; HUMANS; MIDDLE AGED; PLACEBOS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVEYS AND QUESTIONNAIRES; TAMOXIFEN; TREATMENT OUTCOME; VAGINA; VULVA;

EID: 84924663235     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.954996     Document Type: Article

References (28)

1. Santoro N, K omi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6: 2133-42
2. Mac Bride MB, R hodes DJ, S huster L T. V ulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94
3. Soules MR, Bremner WJ. The menopause and climacteric: endocrinologic basis and associated symptomatology. J Am Geriatr Soc 1982; 30: 547-61
4. US Census Bureau. S tatisitical Abstract of the United States: 2012. Available at: http://www.census.gov/compendia/statab/2012/tables/12s0104.pdf. Accessed April 21, 2014
5. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010; 19: 425-32
6. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: fi ndings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10: 1790-9
7. Levine KB, Williams R E, Hartmann K E. V ulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008; 15: 661-6
8. Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 2014; 2: 1137-42
9. Thomas H M, Bryce CL, Ness RB, Hess R. Dyspareunia is associated with decreased frequency of intercourse in the menopausal transition. Menopause 2011; 18: 152-7
10. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 888-902
11. Mathur RS, Landgrebe SC, Moody LO, Semmens JP, Williamson HO. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 1985; 7: 129-33
12. Hickey M, D avis S R, S turdee D W. T reatment of menopausal symptoms: what shall we do now? Lancet 2005; 366: 409-21
13. Berman J R, Bassuk J. Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002; 20: 111-18
14. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208
15. OsphenaT M (ospemifene). Full Prescribing Information, Shionogi Inc., Florham Park, NJ, 2013
16. Portman D J, B achmann G A, S imon J A, and t he Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-30
17. Portman D, P alacios S, N appi R E, M ueck A O. O spemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial. Maturitas 2014; 78: 91-8
18. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005; 31: 1-20
19. North American Menopause Society. T he role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14:355-69
20. McCall-Hosenfeld JS, Jaramillo SA, Legault C, et al. Correlates of sexual satisfaction among sexually active postmenopausal women in the Women's Health Initiative-Observational Study. J Gen Intern Med 2008; 23: 2000-9
21. Schneidewind-Skibbe A, Hayes RD, Koochaki PE, Meyer J, Dennerstein L. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J Sex Med 2008; 5: 301-35
22. Martins WP, Lara LA, Ferriani RA, et al. Hormone therapy for female sexual function during perimenopause and postmenopause: a Cochrane review. Climacteric 2014; 17: 133-5
23. Hays J, O ckene J K, B runner R L, et a l. E ffects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-54
24. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012; 120: 595-603
25. Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause 2014; 21: 309-19
26. B achmann GA, Komi JO, and the Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: 480-6
27. Goldstein S R, B achmann G A, K oninckx P R, e t a l. O spemifene 12-month safety and effi cacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014; 17: 173-82
28. Lee A W, P faff D W. H ormone effects on specifi c and global brain functions. J Physiol Sci 2008; 58: 213-20